Breast - Biopsy
AI algorithm for breast cancer detection in biopsy specimens
Software · HybridCompany source
Company profile
About Deep Bio
Deep Bio is a South Korea-based artificial intelligence healthcare company pioneering AI-powered solutions for cancer pathology diagnostics. The company develops the DeepDx® suite of diagnostic support software that analyzes whole slide images (WSIs) of tissue specimens to detect and classify cancer with high accuracy. Their flagship products focus on prostate and breast cancer pathology, utilizing deep learning algorithms to analyze H&E-stained slides and provide automated Gleason scoring, tumor quantification, and grade group classification. Deep Bio's technology empowers pathologists by providing metrics that are difficult to measure manually, optimizing diagnostic accuracy and treatment decisions. The company's solutions support multiple clinical workflows including first read, concurrent read, quality control, research and development, and education. Their algorithms have been extensively validated through peer-reviewed publications in prestigious medical journals and have achieved regulatory approvals including CE marking and Korea MFDS approval. The company is expanding its product portfolio to include IHC analysis for biomarkers such as Ki-67, ER, PR, HER2, PD-L1, and c-MET across multiple cancer types. Deep Bio also offers DeepCDx™, an AI-enabled drug discovery platform that combines pathology image analysis with clinical data to accelerate pharmaceutical development. With over 700,000 cores analyzed, 38 patents, 25+ publications, and partnerships with leading organizations like Roche and PathAI, Deep Bio is advancing the integration of AI into clinical pathology practice globally.
Company description Deep Bio official website
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Work at Deep Bio?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Breast cancer
- Lung cancer (NSCLC)
- Ovarian cancer
- Prostate cancer
- Stomach cancer
Who it serves
- Health systems
- Hospitals
- Pathology laboratories
- Pharmaceutical companies
- Research institutions
Deployment & integration
Hybrid · Other deployment with recorded integration context.
Geographic context
MarketsEurope · Global (research use) · South Korea
Company sourceOfficial website
Company milestones
Platform expansion
Collaboration with Roche announced September 2024, collaboration with PathAI announced November 2024, MOU with ABION for AI-driven companion diagnostics September 2024, multiple research presentations at AACR 2025, USCAP 2025, AUA 2024, ECP 2024
Partnerships
Recorded partners
- ABION
- PathAI
- Roche
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Breast ER IHC
AI model for ER receptor status measurement in breast cancer
Software · HybridCompany source
Breast HER2 IHC
Advanced AI algorithm for HER2 segmentation and scoring in breast cancer
Software · HybridCompany source
Breast Ki-67 IHC
AI algorithm for automated Ki-67 expression detection and quantification
Software · HybridCompany source
Breast PR IHC
AI model for PR receptor status measurement in breast cancer
Software · HybridCompany source
DeepCDx
AI-enabled drug discovery and companion diagnostics platform
Platform · OtherCompany source
DeepCDx Membrane IHC
Next-generation AI platform for immunohistochemistry analysis
Platform · OtherCompany source
DeepDx Breast - Resection
AI software for breast cancer resection specimen analysis
Software · HybridCompany source
DeepDx Breast - SLNB
AI software for sentinel lymph node biopsy analysis in breast cancer
Software · HybridCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Artificial intelligence-driven digital pathology in urological cancers: current trends and future directions.Prostate international · Dec 1, 2025
Assessing the risk of recurrence in early-stage breast cancer through H&E stained whole slide images.Scientific reports · Oct 8, 2025
Clinical implications of deep learning based image analysis of whole radical prostatectomy specimens.Scientific reports · Mar 31, 2025
MurSS: A Multi-Resolution Selective Segmentation Model for Breast Cancer.Bioengineering (Basel, Switzerland) · May 7, 2024
RCKD: Response-Based Cross-Task Knowledge Distillation for Pathological Image Analysis.Bioengineering (Basel, Switzerland) · Nov 2, 2023
Yet Another Automated Gleason Grading System (YAAGGS) by weakly supervised deep learning.NPJ digital medicine · Jun 14, 2021
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
99% sensitivity, 97% specificity
Prostate cancer detection in core needle biopsies
Quadratic weighted kappa 0.79
Agreement with uropathologist consensus for radical prostatectomy
Kappa 0.927
Benign vs malignant classification
Kappa 0.858
Low-risk vs high-risk disease classification
IoU 0.8
Cancer coverage in prostatectomy specimens
30 seconds per core
AI analysis processing time
Dr. Fouad Kettani
Testing and validation of DeepDx Prostate solution in clinical practice
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Deep Bio
Recent articles published on Deep Bio's official website.
[Posters] AACR 2025 – Artificial intelligence-based quantification of PD-L1 staining intensity in non-small cell lung cancer: Beyond binary assessment
Read on Deep Bio[Posters] USCAP 2025 – A Study on Improving the Performance of Breast Lesion Classification Using Nuclei Information
Read on Deep Bio[Posters] USCAP 2025 – A Deep Learning-Based IHC Tumor Cellular Membranous Staining Analysis for PD-L1 Assessment in Non-Small Lung Cancer
Read on Deep BioDeep Bio’s AI Algorithm Demonstrates Significant Prognostic Advancements in Prostate Cancer Study
Read on Deep Bio[Posters] AACR 2025 – Deep Learning Model for Cancer Diagnosis in Frozen Section Sentinel Lymph Nodes with Limited
Read on Deep Bio07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.